The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Moxibustion to treat diabetes mellitus

    It’s commonly done in East Asian countries.

    Researchers at Kyung Hee University, in Seoul, South Korea, reviewed the evidence.

    First, the details.

    • 5 studies, all poorly designed, were available for review.

    And, the results.

    • Moxibustion + oral administration of micronase (glibenclamide, Glyburide) showed significant effects of moxibustion on control of blood sugar.
    • Moxibustion showed significant improvement in fasting and postprandial blood glucose levels vs conventional treatment.
    • Moxibustion + acupuncture showed the more favorable effects on the control of blood glucose, urine glucose, and A1c than either treatment alone in 2 studies.
    • A final observational study reported positive effects with moxibustion.

    The bottom line?

    The authors concluded, “It is difficult to conclude that moxibustion is an effective intervention for the control of type 2 diabetes mellitus due to the scarcity of trials and the low methodological quality of included studies.”

    It’s not worth the time to conduct poorly designed studies. The outcomes are meaningless.

    8/10/11 21:41 JR

    Leave a Comment

    You must be logged in to post a comment.